Abstract 3333: Birinapant, a novel bivalent Smac mimetic drug, is superior to monovalent Smac mimetics in inhibition of NF-kB by targeting TRAF2-bound cIAP1 and cIAP2.
Cancer Res (2013) 73 (8_Supplement): 3333.
Currently there are no citedby results. Try again later.
RSS Feeds